Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: IDP093
MIFTS: 29

Idiopathic Gastroparesis

Categories: Gastrointestinal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Idiopathic Gastroparesis

About this section

MalaCards integrated aliases for Idiopathic Gastroparesis:

Name: Idiopathic Gastroparesis 58

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Gastrointestinal diseases
See all MalaCards categories (disease lists)
Orphanet: 58  
Rare gastroenterological diseases


External Ids:

Orphanet 58 ORPHA558411
Sources

Summaries for Idiopathic Gastroparesis

About this section
MalaCards based summary : Idiopathic Gastroparesis is related to gastroparesis and constipation. An important gene associated with Idiopathic Gastroparesis is GHRL (Ghrelin And Obestatin Prepropeptide), and among its related pathways/superpathways are cAMP signaling pathway and Angiogenesis (CST). The drugs Prucalopride and Laxatives have been mentioned in the context of this disorder. Affiliated tissues include colon and testes, and related phenotypes are digestive/alimentary and homeostasis/metabolism

Sources

Related Diseases for Idiopathic Gastroparesis

About this section

Diseases related to Idiopathic Gastroparesis via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 22)
# Related Disease Score Top Affiliating Genes
1 gastroparesis 28.9 MRC1 HMOX1 GIP GHSR GHRL
2 constipation 10.0
3 alzheimer disease 9 10.0 GHSR GHRL
4 growth hormone secreting pituitary adenoma 10.0 GHSR GHRL
5 postgastrectomy syndrome 10.0 GIP GHRL
6 pituitary adenoma 9.9 GHSR GHRL
7 dumping syndrome 9.9 GIP GHRL
8 migraine with or without aura 1 9.9
9 cyclic vomiting syndrome 9.9
10 hyperinsulinism 9.9
11 adenocarcinoma 9.9
12 pancreatic adenocarcinoma 9.9
13 neuromuscular disease 9.9
14 median arcuate ligament syndrome 9.9
15 hypoganglionosis 9.9
16 autonomic dysfunction 9.9
17 ileus 9.8 GHSR GHRL
18 functional gastric disease 9.6 GIP GHSR GHRL
19 acromegaly 9.6 GHSR GHRL
20 ectodermal dysplasia 1, hypohidrotic, x-linked 9.4 MRC1 HMOX1
21 ectodermal dysplasia 10b, hypohidrotic/hair/tooth type, autosomal recessive 9.3 MRC1 HMOX1
22 body mass index quantitative trait locus 11 9.0 HMOX1 GIP GHSR GHRL

Graphical network of the top 20 diseases related to Idiopathic Gastroparesis:



Diseases related to Idiopathic Gastroparesis
Sources

Symptoms & Phenotypes for Idiopathic Gastroparesis

About this section

MGI Mouse Phenotypes related to Idiopathic Gastroparesis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.26 GHRL GHSR GIP PDGFRA
2 homeostasis/metabolism MP:0005376 9.1 GHRL GHSR GIP HMOX1 MRC1 PDGFRA
Sources

Drugs & Therapeutics for Idiopathic Gastroparesis

About this section

Drugs for Idiopathic Gastroparesis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prucalopride Approved Phase 4 179474-81-8
2 Laxatives Phase 4
3 Cathartics Phase 4
4 Neurotransmitter Agents Phase 4
5 Gastrointestinal Agents Phase 4
6 Antacids Phase 4
7 Anti-Ulcer Agents Phase 4
8 Serotonin Receptor Agonists Phase 4
9
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
10
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
11
Nortriptyline Approved Phase 3 72-69-5 4543
12 Antidepressive Agents Phase 3
13 Adrenergic Agents Phase 3
14 Antidepressive Agents, Tricyclic Phase 3
15 neurokinin A Phase 3
16
Substance P Phase 3 33507-63-0 44359816
17
Metoclopramide Approved, Investigational Phase 2 364-62-5 4168
18
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
19
Maleic acid Experimental, Investigational Phase 2 110-17-8, 110-16-7 444972
20
Metopimazine Experimental Phase 2 14008-44-7
21 Cola Phase 2
22 Dopamine Antagonists Phase 2
23 Dopamine Agents Phase 2
24 Tea Phase 1
25
Sodium citrate Approved, Investigational 68-04-2
26
Methylene blue Approved, Investigational 61-73-4
27
Esomeprazole Approved, Investigational 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
28
Acetylcholine Approved, Investigational 51-84-3 187
29
Pioglitazone Approved, Investigational Early Phase 1 111025-46-8 4829
30
Olanzapine Approved, Investigational 132539-06-1 4585
31
Citric acid Approved, Nutraceutical, Vet_approved 77-92-9 311
32 Mosapride Investigational 112885-41-3
33 Citrate
34 Proton Pump Inhibitors
35 abobotulinumtoxinA
36 Cholinergic Agents
37 Botulinum Toxins, Type A
38 Botulinum Toxins
39 Hypoglycemic Agents Early Phase 1
40 Psychotropic Drugs
41 Antiemetics
42 Antipsychotic Agents
43 Serotonin Uptake Inhibitors

Interventional clinical trials:

(show all 26)
# Name Status NCT ID Phase Drugs
1 Prucalopride Versus Placebo in Functional Dyspepsia With Delayed Gastric Emptying Unknown status NCT02510976 Phase 4 prucalopride;placebo
2 Double-Blind, Randomized, Placebo-Controlled Trial To Assess Efficacy And Safety Of R051619 (Cisapride 10 mg q.i.d.) Versus Placebo For The Improvement Of Symptoms Associated With Exacerbations Of Idiopathic Gastroparesis, After Failure Of Other Treatment Options Terminated NCT01281540 Phase 4 Cisapride;Placebo
3 Sancuso® in Patients With Nausea and/or Vomiting From Gastroparesis: An Open Label Study. Unknown status NCT01989221 Phase 3 Sancuso®
4 Nortriptyline for Idiopathic Gastroparesis: A Multicenter, Randomized, Double-Masked, Placebo-Controlled Trial (NORIG) Completed NCT00765895 Phase 3 Nortriptyline Hydrochloride;Placebo (for nortriptyline)
5 Double-Blind Placebo-Controlled Cross-Over Design With Wash-Out for Temporary Gastric Electrical Stimulation for Drug Refractory Gastroparesis Completed NCT00432835 Phase 3
6 VP-VLY-686-3301: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Iii Study To Assess The Efficacy Of Tradipitant In Relieving Symptoms Of Gastroparesis Recruiting NCT04028492 Phase 3 Tradipitant;Placebo
7 A Multicenter, Double-Blind, Randomized, Placebo- Controlled, Phase 2 Study to Evaluate Velusetrag Effects on Gastric Emptying in Subjects With Diabetic or Idiopathic Gastroparesis Completed NCT01718938 Phase 2 velusetrag dose 1;velusetrag dose 2;velusetrag dose 3;placebo
8 A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic or Idiopathic Gastroparesis Completed NCT02267525 Phase 2 Velusetrag;Placebo
9 A Dose-Ranging, Randomized, Parallel, Placebo-Controlled Study to Assess the Effect of TAK-954 on Gastrointestinal and Colonic Transit in Patients With Diabetic or Idiopathic Gastroparesis Completed NCT03281577 Phase 2 TAK-954;Placebo
10 A 2-Part, Randomized, Double Blind and Open-Label, Placebo and Active-Comparator Controlled Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics for TAK-906 in Subjects With Diabetes Mellitus and Gastroparesis or With Idiopathic Gastroparesis Completed NCT03268941 Phase 2 TAK-906 Maleate;Metaclopramide;TAK-906 Maleate Placebo
11 Acupuncture Treatment for Gastroparesis: a Pilot Study Completed NCT01643577 Phase 1, Phase 2
12 A Phase 2 Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study, of the Safety and Efficacy of NG101 Administered Orally to Patients With Gastroparesis Not yet recruiting NCT04303195 Phase 2 NG101
13 Transcutaneous Electroacupuncture for Gastroparesis Completed NCT01469286 Phase 1
14 Effects of Global Osteopathic Manual Treatments on Patients With Idiopathic Gastroparesis Unknown status NCT02232334
15 Cooperative Group for Clinical Research in G-POEM (POP), Jiangsu, China Unknown status NCT03040817 Esomeprazole + Mosapride
16 Study of the Antro-pyloro-duodenal Motor Dysfunction in Idiopathic Gastroparesis Completed NCT01519180
17 GpR 2: Continuation of the NIDDK Gastroparesis Registry for the Characterization and Clinical Course of Gastroparesis Patients Completed NCT01696747
18 Endoscopic Full Thickness Biopsy of the Gastric Wall in Patients With Refractory Idiopathic Gastroparesis: Pilot Study to Detect Neuromuscular and Immune Pathologic Changes Completed NCT01650714
19 Intraluminal Endosonography for Examination of the Structural Changes of the Stomach in Gastroparetic Patients Completed NCT01916460
20 Randomized Placebo-Controlled Double Blind Study of Botulinum Toxin Versus Placebo for the Treatment of Gastroparesis Completed NCT00372970 Botulinum toxin A;Placebo
21 Evaluation of Liquid Gastric Emptying and Plasma Ghrelin in Children With Functional Dyspepsia Completed NCT01591174
22 Pioglitazone for the Treatment of Idiopathic Gastroparesis (PIOGAS Study) Recruiting NCT04300127 Early Phase 1 Pioglitazone 30 mg
23 Pediatric Gastroparesis Registry: Pediatric Registry of Patients With Suspected Gastroparesis Recruiting NCT03680820
24 A Randomized, Sham and Cross-Over-Controlled Trial of Per-oral Endoscopic Pyloromyotomy (G-POEM) in Patients With Refractory Gastroparesis Recruiting NCT03356067
25 Idiopathic Gastroparesis Registry to Define Severity, Treatment Response, and Prognosis Using a Predominant-Symptom Classification Terminated NCT01173484
26 A Pilot Study on the Efficacy and Safety of Olanzapine in Improving Symptoms and Gastric Motility in Gastroparesis Terminated NCT01625923 Olanzapine

Search NIH Clinical Center for Idiopathic Gastroparesis

Sources

Genetic Tests for Idiopathic Gastroparesis

About this section
Sources

Anatomical Context for Idiopathic Gastroparesis

About this section

MalaCards organs/tissues related to Idiopathic Gastroparesis:

40
Colon, Testes
Sources

Publications for Idiopathic Gastroparesis

About this section

Articles related to Idiopathic Gastroparesis:

(show top 50) (show all 150)
# Title Authors PMID Year
1
Epidemiology and outcomes of gastroparesis, as documented in general practice records, in the United Kingdom. 61
32493829 2020
2
Gastric peroral endoscopic pyloromyotomy versus gastric electrical stimulation in the treatment of refractory gastroparesis: a propensity score-matched analysis of long term outcomes. 61
32084672 2020
3
An emerging method to noninvasively measure and identify vagal response markers to enable bioelectronic control of gastroparesis symptoms with gastric electrical stimulation. 61
32087238 2020
4
Open-label pilot study: Non-invasive vagal nerve stimulation improves symptoms and gastric emptying in patients with idiopathic gastroparesis. 61
31802596 2020
5
Symptom variability throughout the day in patients with gastroparesis. 61
31782211 2020
6
The Role of GI Peptides in Functional Dyspepsia and Gastroparesis: A Systematic Review. 61
32256403 2020
7
Safety and Feasibility of Per-Oral Pyloromyotomy as Augmentative Therapy after Prior Gastric Electrical Stimulation for Gastroparesis. 61
31610231 2019
8
Proteomics in gastroparesis: unique and overlapping protein signatures in diabetic and idiopathic gastroparesis. 61
31482734 2019
9
Clinical efficacy of gastric per-oral endoscopic myotomy (G-POEM) in the treatment of refractory gastroparesis and predictors of outcomes: a systematic review and meta-analysis using surgical pyloroplasty as a comparator group. 61
31583465 2019
10
Surgical Treatment for Refractory Gastroparesis: Stimulator, Pyloric Surgery, or Both? 61
31512100 2019
11
Functional Emesis. 61
31517329 2019
12
Prucalopride in Gastroparesis: A Randomized Placebo-Controlled Crossover Study. 61
31295161 2019
13
Abdominal Pain in Patients with Gastroparesis: Associations with Gastroparesis Symptoms, Etiology of Gastroparesis, Gastric Emptying, Somatization, and Quality of Life. 61
30852767 2019
14
Transcriptome profiling reveals significant changes in the gastric muscularis externa with obesity that partially overlap those that occur with idiopathic gastroparesis. 61
31221130 2019
15
Opioid Use and Potency Are Associated With Clinical Features, Quality of Life, and Use of Resources in Patients With Gastroparesis. 61
30326297 2019
16
Case Report of gastroparesis healing: 16 years of a chronic syndrome resolved after proximal intercessory prayer. 61
30935546 2019
17
Diabetic Gastroparesis and Nondiabetic Gastroparesis. 61
30396524 2019
18
Epidemiology and Pathophysiology of Gastroparesis. 61
30396519 2019
19
Pathophysiology of idiopathic gastroparesis and implications for therapy. 61
30638082 2019
20
Bayesian inverse methods for spatiotemporal characterization of gastric electrical activity from cutaneous multi-electrode recordings. 61
31609972 2019
21
Sepiapterin alleviates impaired gastric nNOS function in spontaneous diabetic female rodents through NRF2 mRNA turnover and miRNA biogenesis pathway. 61
30285465 2018
22
Pyloric sphincter characteristics using EndoFLIP® in gastroparesis. 61
29709494 2018
23
Wisconsin's Enterra Therapy Experience: A multi-institutional review of gastric electrical stimulation for medically refractory gastroparesis. 61
30072246 2018
24
Efficacy of needleless transcutaneous electroacupuncture in synchronization with breathing for symptomatic idiopathic gastroparesis: A blinded and controlled acute treatment trial. 61
29745434 2018
25
Rome IV Diagnostic Questionnaire Complements Patient Assessment of Gastrointestinal Symptoms for Patients with Gastroparesis Symptoms. 61
29808246 2018
26
Transcriptomic signatures reveal immune dysregulation in human diabetic and idiopathic gastroparesis. 61
30086735 2018
27
Idiopathic gastroparesis is associated with specific transcriptional changes in the gastric muscularis externa. 61
29052298 2018
28
Therapeutic response to domperidone in gastroparesis: A prospective study using the GCSI-daily diary. 61
29110425 2018
29
Per oral endoscopic pyloromyotomy for refractory gastroparesis: initial results from a single institution. 61
28567693 2017
30
Gastroparesis: Medical and Therapeutic Advances. 61
28721575 2017
31
Gastric neuromuscular histology in patients with refractory gastroparesis: Relationships to etiology, gastric emptying, and response to gastric electric stimulation. 61
28374487 2017
32
Diabetic and idiopathic gastroparesis is associated with loss of CD206-positive macrophages in the gastric antrum. 61
28066953 2017
33
Early satiety and postprandial fullness in gastroparesis correlate with gastroparesis severity, gastric emptying, and water load testing. 61
27781342 2017
34
Repeat polymorphisms in the Homo sapiens heme oxygenase-1 gene in diabetic and idiopathic gastroparesis. 61
29161307 2017
35
Gastroparesis as the Sole Presenting Feature of Neuromyelitis Optica. 61
29026864 2017
36
Evaluation of prokinetic agents used in the treatment of gastroparesis. 61
28265483 2017
37
Nausea and vomiting in gastroparesis: similarities and differences in idiopathic and diabetic gastroparesis. 61
27350152 2016
38
Gastric Electrical Stimulation for Gastroparesis and Chronic Unexplained Nausea and Vomiting. 61
27678506 2016
39
Measures of Autonomic Dysfunction in Diabetic and Idiopathic Gastroparesis. 61
27785328 2016
40
Innovative gastric endoscopic muscle biopsy to identify all cell types, including myenteric neurons and interstitial cells of Cajal in patients with idiopathic gastroparesis: a feasibility study (with video). 61
27129395 2016
41
Gastric peroral endoscopic pyloromyotomy (G-POEM) as a salvage therapy for refractory gastroparesis: a case series of different subtypes. 61
27197717 2016
42
Pancreatic Adenocarcinoma Invading the Duodenum and Presenting as Idiopathic Gastroparesis with Nausea and Vomiting. 61
27807571 2016
43
Gastric Enterovirus Infection: A Possible Causative Etiology of Gastroparesis. 61
27344315 2016
44
[Gastroparesis - causes, diagnosis and treatment]. 61
27221182 2016
45
Hydration Strategy for Endurance Running in an Athlete Requiring Home Parenteral Nutrition. 61
26150104 2016
46
Gastroparesis. 61
26406565 2015
47
Gastric electrical stimulation for refractory gastroparesis: predictors of response and redefining a successful outcome. 61
25975330 2015
48
Cardiovascular safety profile and clinical experience with high-dose domperidone therapy for nausea and vomiting. 61
25828198 2015
49
Foods provoking and alleviating symptoms in gastroparesis: patient experiences. 61
25840923 2015
50
Assessing pyloric sphincter pathophysiology using EndoFLIP in patients with gastroparesis. 61
25712043 2015
Sources

Variations for Idiopathic Gastroparesis

About this section
Sources

Expression for Idiopathic Gastroparesis

About this section
Search GEO for disease gene expression data for Idiopathic Gastroparesis.
Sources

Pathways for Idiopathic Gastroparesis

About this section

Pathways related to Idiopathic Gastroparesis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
cAMP signaling pathway 36
11.47 GIP GHSR GHRL
2
Angiogenesis (CST) 4
11.11 PDGFRA HMOX1
3
Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics 60
9.92 GHSR GHRL
Sources

GO Terms for Idiopathic Gastroparesis

About this section

Cellular components related to Idiopathic Gastroparesis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.33 PDGFRA MRC1 GHSR
2 postsynapse GO:0098794 9.26 GHSR GHRL
3 secretory granule lumen GO:0034774 8.96 GIP GHRL
4 Schaffer collateral - CA1 synapse GO:0098685 8.62 GHSR GHRL

Biological processes related to Idiopathic Gastroparesis according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of inflammatory response GO:0050728 9.64 GHSR GHRL
2 female pregnancy GO:0007565 9.63 GIP GHSR
3 response to nutrient levels GO:0031667 9.63 GIP GHRL
4 response to estrogen GO:0043627 9.62 HMOX1 GHRL
5 response to hormone GO:0009725 9.62 GHSR GHRL
6 hormone-mediated signaling pathway GO:0009755 9.61 GHSR GHRL
7 positive regulation of insulin secretion GO:0032024 9.61 GIP GHRL
8 positive regulation of multicellular organism growth GO:0040018 9.6 GHSR GHRL
9 negative regulation of insulin secretion GO:0046676 9.59 GHSR GHRL
10 positive regulation of sprouting angiogenesis GO:1903672 9.58 GHSR GHRL
11 decidualization GO:0046697 9.58 GHSR GHRL
12 positive regulation of vascular endothelial cell proliferation GO:1905564 9.57 GHSR GHRL
13 actin polymerization or depolymerization GO:0008154 9.56 GHSR GHRL
14 regulation of postsynapse organization GO:0099175 9.55 GHSR GHRL
15 negative regulation of interleukin-6 biosynthetic process GO:0045409 9.54 GHSR GHRL
16 negative regulation of interleukin-1 beta production GO:0032691 9.52 GHSR GHRL
17 negative regulation of tumor necrosis factor secretion GO:1904468 9.51 GHSR GHRL
18 positive regulation of growth GO:0045927 9.49 GHSR GHRL
19 adult feeding behavior GO:0008343 9.48 GHSR GHRL
20 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.46 GHSR GHRL
21 postsynaptic modulation of chemical synaptic transmission GO:0099170 9.43 GHSR GHRL
22 growth hormone secretion GO:0030252 9.4 GHSR GHRL
23 positive regulation of eating behavior GO:1904000 9.37 GHSR GHRL
24 regulation of transmission of nerve impulse GO:0051969 9.32 GHSR GHRL
25 positive regulation of appetite GO:0032100 9.26 GHSR GHRL
26 regulation of gastric motility GO:1905333 9.16 GHSR GHRL
27 positive regulation of small intestine smooth muscle contraction GO:1904349 8.96 GHSR GHRL
28 positive regulation of small intestinal transit GO:0120058 8.62 GHSR GHRL

Molecular functions related to Idiopathic Gastroparesis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.62 GIP GHRL
Sources

Sources for Idiopathic Gastroparesis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....